ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO640

Comparison between Standard of Care Treatment and Dapagliflozin Added to Standard of Care in Patients with Lupus Nephritis: A Randomized Controlled Trial

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Rathi, Manish, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
  • A V, Niranjan, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
  • Divyaveer, Smita Subhash, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
  • Sharma, Aman, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
Background

The exploration of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) presents a novel avenue in treating Lupus Nephritis (LN). This study investigates the potential role of adding Dapagliflozin to the SOC treatment in management of LN patients.

Methods

We conducted a randomised controlled open-label study by enrolling 32 newly diagnosed LN patients. Among them, 17 received Dapagliflozin in addition to SOC, while 15 received SOC alone. The patients were followed up monthly for 6 months. The primary outcome was the treatment response at 6 months as per the KDIGO guidelines.

Results

Baseline characteristics revealed no significant demographic differences between the two groups. While both groups exhibited prevalent lupus-related symptoms, the intervention group demonstrated significantly lower mean systolic blood pressure and total protein levels at baseline. At the 6-month follow-up, the clinical response rate in the intervention group was 81.8%, with a trend toward better outcomes compared to the standard of care group (60%) (p 0.425). Frequency of urinary tract infections was higher in the dapagliflozin arm (p 0.31). No significant differences were observed in other parameters between the groups at the 6 months.

Conclusion

In conclusion, this pilot study suggests that the addition of Dapagliflozin to standard care may improve clinical responses in LN with acceptable adverse effects.

Figure 1: Consort Diagram

Table 1: Baseline characteristics